Trial Outcomes & Findings for Hyperbaric Oxygen Therapy in Sickle Cell Pain (NCT NCT03412045)
NCT ID: NCT03412045
Last Updated: 2026-07-28
Results Overview
Comparison of total analgesic administered to patient during control hospital stay versus intervention HBO treatment hospital stay. Each patient serves as their own control. The patient receives HBO treatment during one hospital admission, and the amount of analgesic received is compared to the patient's previous hospital admission.
COMPLETED
NA
8 participants
admission to discharge
2026-07-28
Participant Flow
Participant milestones
| Measure |
Patients Experiencing Acute Sickle Cell Crisis
Enrolled participants will receive 1-3 hyperbaric oxygen sessions
|
|---|---|
|
Overall Study
STARTED
|
8
|
|
Overall Study
COMPLETED
|
8
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Specific patient age not collected, only confirmed age was 19 yrs or older
Baseline characteristics by cohort
| Measure |
Patients Experiencing Acute Sickle Cell Crisis
n=8 Participants
Enrolled participants are patients admitted for treatment of acute sickle cell crisis.
|
|---|---|
|
Age, Customized
19 years and older
|
8 Participants
n=8 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=8 Participants • Specific patient age not collected, only confirmed age was 19 yrs or older
|
|
Sex: Female, Male
Male
|
5 Participants
n=8 Participants • Specific patient age not collected, only confirmed age was 19 yrs or older
|
PRIMARY outcome
Timeframe: admission to dischargeComparison of total analgesic administered to patient during control hospital stay versus intervention HBO treatment hospital stay. Each patient serves as their own control. The patient receives HBO treatment during one hospital admission, and the amount of analgesic received is compared to the patient's previous hospital admission.
Outcome measures
| Measure |
Treatment
n=7 Participants
This preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen (HBO), the intervention, in an effort to ameliorate pain and shorten the length of hospital stay.
|
|---|---|
|
Analgesic Received in MME (Morphine Milligram Equivalents)
|
-193.00 MME (morphine milligram equivalents)
Interval -2020.0 to 80.0
|
SECONDARY outcome
Timeframe: admission to dischargePopulation: The length of stay was reduced by 44 hours between the control and treatment hospital stays.
Comparison of hospital length of stay in days during control hospital stay versus intervention HBO treatment hospital stay. Each patient serves as their own control. The patient receives HBO treatment during one hospital admission, and that length of stay is compared to the patient's previous hospital admission.
Outcome measures
| Measure |
Treatment
n=7 Participants
This preliminary study will be a convenience sample of patients admitted to hospital for vaso-occlusive sickle cell crisis to be treated with hyperbaric oxygen (HBO), the intervention, in an effort to ameliorate pain and shorten the length of hospital stay.
|
|---|---|
|
Hospital Length of Stay
|
-44.0 hours
Interval -51.2 to 1.1
|
Adverse Events
Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Jeffrey Cooper
University of Nebraska Medical Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place